Pervasive wearable device for free tissue transfer monitoring based on advanced data analysis: clinical study report

Melissa Berthelot
Francis Patrick Henry
Judith Hunter
Daniel Leff
Simon Wood
Navid Jallali
Elizabeth Dex
Ladislava Lysakova
Benny Lo
Guang-Zhong Yang

Pervasive wearable device for free tissue transfer monitoring based on advanced data analysis: clinical study report

Melissa Berthelot,^{a,*} Francis Patrick Henry,^b Judith Hunter,^b Daniel Leff,^b Simon Wood,^b Navid Jallali,^b Elizabeth Dex,^b Ladislava Lysakova,^b Benny Lo,^a and Guang-Zhong Yang^a

^aImperial College London, The Hamlyn Centre, South Kensington Campus, London, United Kingdom

^bImperial College Healthcare NHS Trust London, Charing Cross Hospital, London, United Kingdom

Abstract. Free tissue transfer (FTT) surgery for breast reconstruction following mastectomy has become a routine operation with high success rates. Although failure is low, it can have a devastating impact on patient recovery, prognosis, and psychological well-being. Continuous and objective monitoring of tissue oxygen saturation (StO₂) has been shown to reduce failure rates through rapid detection time of postoperative vascular complications. We have developed a pervasive wearable wireless device that employs near-infrared spectroscopy (NIRS) to continuously monitor FTT via StO₂ measurement. Previously tested on different models, the results of a clinical study are introduced. Our goal for the study is to demonstrate that the developed device can reliably detect StO₂ variations in a clinical setting: 14 patients were recruited. Advanced data analysis was performed on the StO₂ variations, the relative StO₂ gradient change, and the classification of the StO₂ within different clusters of blood occlusion level (from 0% to 100% at 25% step) based on previous studies made on a vascular phantom and animals. The outcomes of the clinical study concur with previous experimental results and the expected biological responses. This suggests that the device is able to correctly detect perfusion changes and provide real-time assessment on the viability of the FTT in a clinical setting. © The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: [10.1117/1.JBO.24.6.067001](https://doi.org/10.1117/1.JBO.24.6.067001)]

Keywords: spectroscopy; near-infrared spectroscopy; free tissue transfer; breast reconstruction surgery; wearable device; internet of things.

Paper 190066R received Mar. 12, 2019; accepted for publication May 16, 2019; published online Jun. 19, 2019.

1 Introduction

Free tissue transfer (FTT) surgery is commonly performed following trauma or cancer to reconstruct defects. Focusing on breast reconstruction after mastectomy, the autologous FTT consists in harvesting soft tissue, including blood vessels, from a distant body region, and anastomosis to the recipient area for reconstruction (see Fig. 2). The anastomosis involves the suturing of at least a pair of blood vessels (vein and artery) onto the recipient site. FTT survival depends on the patency of the blood vessels following the anastomosis. Compromised blood flow of the vein or/and artery reduces normal perfusion of oxygen and nutrients within the tissue, which will induce necrosis. FTT vascular complications (VCs) have mainly been reported within the first 24 to 48 h after surgery, with an increased rate within the first 4 h following the anastomosis.¹ Thrombosis at the venous pedicle causes congested tissue, often inducing hematoma. Thrombosis of the artery causes very pale hypoperfused tissue.² Early detection and intervention of a VC can allow partial or complete salvation of the tissue. To prevent complete FTT failure and allow early detection, close postoperative monitoring is crucial. Although there are no standardized methods, this is often done with clinical observations, which consist of discrete and regular kinetic and visual assessments of the FTT (e.g., tissue color and texture, skin turgor, and capillary refill time).³ However, early detection of a VC also requires experience and

the clinical team cannot continuously observe the patient. Owing to the discrete assessments, methods for continuous monitoring based on the biophysical and biochemical properties of tissue have been developed to ensure early detection of VC and, if needed, prompt intervention from the clinical team.

Microdialysis and tissue oxygen tension are continuous monitoring methods that use chemical reactions to deduce the health of the monitored tissue. These are implantable probes that are placed close to the FTT to detect small variations of concentration of the investigated chemicals, which allow early detection of VC in the case of abnormal relative chemical concentrations. However, the lack of detailed and large studies investigating their sensitivity and efficiency over different surgery types; patients' demographics; and potential risks, costs, and practical usability or limitations reduce its acceptability.^{4,5} The long setup time and recalibration with chemical solutions can also limit its routine use.^{4,5} The Doppler effect has been used to monitor blood perfusion changes. It has been embodied within different modalities: as an implantable probe and as a handheld device. Although the implantable Doppler has shown to be highly sensitive in detecting FTT VC, the best practice for its placement around the pedicle and the learning curve within the clinical team are still an issue.^{6–8} Similarly, the manipulation of the handheld Doppler device is operator-dependent and is sensitive to motion with an unknown penetration depth. Spectroscopy has also been used with near-infrared wavelengths to continuously monitor the concentration variations of different hemoglobin compounds to deduce the relative oxygen saturation in an area

*Address all correspondence to Melissa Berthelot, E-mail: meb14@ic.ac.uk

of tissue (StO_2). Studies have shown that near-infrared spectroscopy (NIRS) devices detect FTT VC early with high sensitivity.⁹ However, the current devices have often overlooked the variations of NIRS results among patients with different demographics [e.g., age, sex, body mass index (BMI), skin color and thickness, smoking or alcohol intake, or physical activity level] and comorbidities (e.g., vascular diseases or diabetes), leading to erroneous interpretation of outcomes.^{10–16} These continuous monitoring devices are commercially available but have limitations and do not provide complete practical benefit for both the patients and the clinical team.³

We have developed a compact wireless wearable device using NIRS that reliably measures the StO_2 independent of the patient's demographics.^{2,17} Previously validated with phantom, animal, and healthy human studies, the results show that the device can distinguish venous from arterial blood and different levels of venous occlusion for detection of FTT VC.^{17,18} This paper introduces the results of the clinical study for postoperative FTT monitoring in the case of breast reconstruction using our developed NIRS device. In addition to showing the device suitability for the clinical setting, it is demonstrated that it can adequately detect StO_2 variations. The use of advanced data analysis provides further real-time and predictive insight on the tissue viability.

2 Device Description

We have developed a wireless wearable device that connects with a tablet for real-time data visualization and remote access.^{19–21} The device has been designed to continuously monitor StO_2 in soft living tissue independently of the patient's demographics. Using spectroscopy, which is the study of the interaction of a given wavelength light with a given environment, properties and composition of the environment can be deduced. When using near-infrared light spectrum on a tissue environment, relative hemoglobin compounds can be measured to deduce StO_2 ; in particular, oxygenated hemoglobin (HbO_2) and deoxygenated hemoglobin (HHb) can be measured respectively using 520 to 600 nm or 620 to 780 nm and 800 to 1000 nm wavelength ranges. The equations are derived as follows:

$$\text{StO}_2 = \eta \frac{\text{HbO}_2}{\text{THb}} + \varepsilon_S, \quad (1)$$

where THb is the total hemoglobin, which is estimated as

$$\text{THb} = \text{HbO}_2 + \text{HHb} + \varepsilon_T, \quad (2)$$

where ε_S and ε_T are the nonsignificant errors, and η is a calibration coefficient for hardware and/or software specifications of the device. Although, other hemoglobin compounds exist, it is assumed that their concentration is insignificant compared to that of HbO_2 and HHb and so their cumulative effect is not explicitly modeled (included in ε_T).

Figure 1(a) shows the electronic board, which has been made waterproof and is embodied within a biocompatible material casing for its use in a clinical setting. The patch-embodied device can be recharged using a designed docking station [see Fig. 1(b)].

The embedded software of the device is based on a closed-loop system allowing self-calibration, independent of the environment conditions or patient's demographics.¹⁷ The device has also been designed to self-recover data, calibration parameters,

Fig. 1 Views of the StO_2 device. (a) Top and bottom views of the electronic board of the device for continuous StO_2 monitoring.¹⁷ (b) Top and bottom view of the patch-embodied device (left top and bottom pictures) coming with its charging station (right top and bottom pictures).

and communication connections in the cases of lost communication, mobile application, or/and embedded software crash.

The sampling and communication rates are at 0.25 Hz, which allow a battery life of 30 to 40 h, depending on the calibration parameters, using a lithium-polymer battery at 3.7 V, 80 mAh. The sampling rate has been optimized to provide a sufficient battery life without losing too much data information. At this rate, 900 data points are recorded per hour, giving about 1Mo of data per 24 h. The sampling rate and the number of data points are sufficient to perform rigorous statistical analysis and data interpretation.

3 Method

Following ethical approval (REC:16/LO/1584), the clinical study, from which results are reported here, took place at Charing Cross Hospital, Imperial College Healthcare NHS Trust. The goal of the study is to show that the device can adequately measure StO_2 variations on FTT for 48 h and be suitable for use within the clinical setting.

3.1 Protocol

Over a 6-month period, patients were approached if they were scheduled to undergo a deep inferior epigastric perforator (DIEP) FTT surgery for immediate or delayed breast reconstruction (see Fig. 2). Following written consent, the patients were enrolled in the study. At the end of the reconstructive surgery, once the patient was ready to go to recovery, the device was

Fig. 2 Schematic representations of harvesting and suturing processes of the DIEP FTT operation for breast reconstruction following mastectomy.

placed on the cutaneous paddle of the FTT, independent to its relative position on the mastectomy defect. The casing is attached with a medical skin adhesive tape from Softleaves. Therefore, the anastomosis was performed between 2 and 3 h prior to the start of the monitoring. The StO_2 measurements were undertaken for about 48 h in total. Following ethical guidelines, the clinical team was not allowed access to the real-time results before the discharge of the patient to avoid affecting outcomes. During the use of the device, conventional clinical monitoring, including the use of a handheld acoustic Doppler, was regularly performed, once every 30 min for the first 6 post-operative hours, every hour for the next 24 h, every 2 h for the next 12 h, and finally every 4 h until discharged, inline with the departmental protocols. Vitals including diastolic and systolic blood pressure (mmHg), heart rate (BPM), respiratory rate (BPM), and peripheral capillary oxygen saturation (SpO_2) were also recorded during the regular assessments. Patient's demographics including age, BMI, sex, skin tone (following the dermatology Fitzpatrick scale²), smoking and alcohol consumptions, and, physical activity level were also recorded (see Table 1).

As no FTT VC happened during the trial, freshly excised discarded tissue from the FTT was monitored. The excised tissue behaved similarly as an FTT with a VC. Within 5 min of being excised, a StO_2 device was placed on the discarded tissue for about 3 h [see Fig. 3(b)]. At the end of the monitoring time, the tissue was disposed following hospital guidelines.

3.2 Patients

A total of 14 patients consented to participate in the study, with 2 patients (ID = 4 and ID = 13) undergoing a bilateral operation; a total of 16 datasets of 48 h of StO_2 measurements were obtained. Patients 1, 5, 6, and 12 had a delayed reconstruction following mastectomy; all the other patients underwent an immediate reconstruction following mastectomy (see Table 1). The reconstructions were performed either by FH, JH, NJ, or SW. All patients had a successful FTT and showed no complications within the first 48 postoperative hours.

Table 1 shows the patients demographics. Recruited patients were on average 49.5 (± 7.2) years old, with a BMI being in the normal range at 35.7% ($N = 5$), overweight at 28.6% ($N = 4$), and obese at 35.7% ($N = 5$), and a skin tone scaled at I for 7.1% ($N = 1$), at II for 35.7% ($N = 5$), at III and IV for 14.3% ($N = 2$), at V for 7.1% ($N = 1$), and at VI for 21.4% ($N = 3$), according to the Fitzpatrick scale. Most patients were nonsmokers at 85.7% ($N = 12$) and the remaining were heavy smokers. Most patients abstained from alcohol at 57.1%

Table 1 Patients' demographics.

PID	Age	BMI	ST	FS	AC	PA	MW	FW
1	49	IV	VI	I	II	I	—	894
2	41	II	II	I	I	II	214	291
3	57	III	II	I	II	II	693	755
4	57	IV	IV	I	I	III	NA	759
							NA	741
5	40	III	III	V	III	II	—	628
6	39	IV	VI	I	I	I	—	867
7	64	III	VI	I	I	IV	806	626
8	50	III	IV	I	II	III	418	612
9	52	II	III	I	III	III	158	268
10	43	IV	I	I	I	III	280	362
11	46	II	II	I	I	V	490	648
12	53	II	II	I	III	III	—	493
13	51	II	II	I	I	III	370	263
							536	269
14	51	IV	V	V	I	I	404	606

Note: PID, patient identification number; BMI, body mass index; which can be I = underweight (<18.5), II = healthy (between 18.5 and 24.9), III = overweight (between 25 and 29.9) or IV = obese (>30); FS, skin tone that follows the Fitzpatrick scale and are I: red/blonde hair, green eyes, and very light skin, II: light/medium colored hair, eyes, and skin, III: medium colored hair, medium to dark eyes, and medium to olive skin, IV: dark hair and eyes and dark olive to light brown skin, V: dark hair, eyes and skin, and VI: dark hair, eyes, and very dark skin;² SC, smoking consumption, scaled from I to V, with I = nonsmoker, II = less than two cigarettes a week, III = two to five cigarettes a week, IV = five to seven cigarettes a week, V = more than seven cigarettes a week; AC, alcohol consumption; scaled from I to V, with I = nondrinker, II = less than two drinks a week, III = two to five drinks a week, IV = five to seven drinks a week, V = more than seven drinks a week; PA, physical activity level; scale from I to V, with I = sedentary, II = < 2 h a week, III = 2 to 5 h a week, IV = 5 to 7 h a week, V => 7 h a week; MW, mastectomy tissue weight in grams; FW, free tissue weight in grams; NA, not available.

($N = 8$). In terms of physical activity level, 42.8% ($N = 6$) exercised 2 to 5 h a week, 14.2% ($N = 2$) did >5 h a week, and the remaining patients were either sedentary or did <2 h of physical activity a week (see Table 1).

3.3 Data Analysis

Each raw dataset was retrieved and analyzed offline. To further ease visualization of the StO_2 percentage over time, an estimation is performed. To do so, every 3 h, a 2-min data point window, called $\bar{P}_{StO_2}$, is averaged

$$\bar{P}_{StO_2}(t) = \frac{1}{N} \sum_t^{t+\theta} P_{StO_2}(t), \tag{3}$$

Fig. 3 Setup of the StO₂ patch-embodied device during the clinical trial. (a) Setup of the StO₂ patch-embodied device on the cutaneous paddle of the FTT after breast reconstructive surgery. (b) Setup of the StO₂ patch-embodied device on human excised discarded tissue—the piece of tissue excluded from the FTT is used to reconstruct the breast defect.

where θ , in this case, is the 2-min window, N , $\forall N \in \mathbb{N}^*$, denotes the total number of points within the 2-min window, and t denotes the time. The difference between two successive $\bar{P}_{\text{StO}_2}$ points gives the differential of StO₂ over the 3 h, called Δ_{StO_2}

$$\Delta_{\text{StO}_2}(\omega) = \bar{P}_{\text{StO}_2}(\omega + 1) - \bar{P}_{\text{StO}_2}(\omega), \quad (4)$$

where ω is the index of the differential of StO₂; $\forall \omega \in \mathbb{N}^*$. This provides an estimation of the rate of StO₂ percentage change over time. In addition, a gradient in the StO₂ differentials over two successive time windows, called Ξ_{StO_2} , is also calculated. It allows observing how much StO₂ differential has evolved

$$\Xi_{\text{StO}_2}(\nu) = \Delta_{\text{StO}_2}(\nu + 1) - \Delta_{\text{StO}_2}(\nu), \quad (5)$$

where ν , $\forall \nu \in \mathbb{N}^*$, is the index of the gradient of the StO₂ differentials. The 3 h and 2 min time windows are chosen empirically for ease in the visualization, as in Fig. 4, but can be changed to any time window without affecting the final results. Finally, the mean StO₂ calculated every 30-min window, called $\bar{\text{StO}_2}$, is obtained using the equivalent of Eq. (3). It scales between 35%, appearing in dark blue, and 95%, appearing in bright yellow.

Previous work on the detection of partial occlusion using synthetic blood and a vascular phantom had been carried out by emulating 0% (release) to 100% blood occlusion levels at 25% steps.^{2,17} These results show that it is possible to distinguish low from high occlusion levels of StO₂ percentage with a two-dimensional naive Bayesian classifier based on 568- and 880-nm light extinctions.¹⁷ Equation (6) derives the naive Bayes classifier's theorem, with the parameters for each class shown in Table 2, as follows:

$$p(C_k|x_1, x_2) = \alpha P(C_k) \prod_{i=1}^2 \frac{1}{\sqrt{2\pi\sigma_{C_k}^2}} \exp\left[-\frac{(x_i - \mu_{C_k})^2}{2\sigma_{C_k}^2}\right], \quad (6)$$

where C_k is the class k , $k = \{0\% \text{ occlusion (or release), } 25\% \text{ occlusion, } 50\% \text{ occlusion, } 75\% \text{ occlusion, } 100\% \text{ occlusion}\}$, x_1 and x_2 are the classifiers' dimensions, which are HHb and HbO₂ based on the light extinctions, α is a normalizing constant, $P(C_k)$ is the prior probability of an observation to be part of class C_k , σ_{C_k} is the variance of the Gaussian distribution of class

C_k , and μ_{C_k} is the mean of the Gaussian distribution of class C_k (see Table 2). Although quantifying the percentage level of occlusion in a blood vessel is impossible in an uncontrolled clinical setting, as blood vessel occlusion is believed to progressively occur,^{22,23} quantifying the approximate blood occlusion level could assist in the early detection of FTT VC. After being retrieved, the StO₂ percentage data acquired on patients are separately placed within the trained classifier for quantification of the blood vessel occlusion level. The StO₂ results of the excised discarded tissue are calculated using Eqs. (1) and (4).

4 Results

Figure 4(a) illustrates the results of all the patients' datasets; the datasets are time-synchronized. Δ_{StO_2} is a differential performed at a regular time interval to provide an estimation of the StO₂ percentage. The StO_2 shows the evolution of the StO₂ percentage for every 30-min window. Displayed with a colored matrix, dark blue is 40% StO₂ and light yellow is 95% StO₂. The Ξ_{StO_2} is a gradient that shows the evolution of the differentials Δ_{StO_2} over time. Displayed with a colored matrix, red is -20% , amber is 0% , and green is $+20\%$ of StO₂ percentage change, compared with the previous differential. The gradient, Ξ_{StO_2} , shows a steady StO₂ percentage evolution with no notable change between successive differentials; yellow cells are often consecutive. When the StO₂ percentage decreases over a few hours (especially visible with StO_2), the Ξ_{StO_2} does not notably negatively change for the same amount of time. This is also similar in the case of StO₂ percentage increase. This suggests that with Ξ_{StO_2} , dramatic StO₂ percentage decrease would be characterized by many consecutive dark red cells.

When looking at each patient dataset separately, the StO₂ percentage increases within the first 24 postoperative hours (on average at $14.6 \text{ h} \pm 8.6 \text{ h}$, with an average $76\% \pm 12\%$ StO₂ percentage). Also, before the StO₂ percentage increases, it slightly decreases (average $10\% \pm 4.6\%$). In general, the StO₂ percentage remains above 20% during the first 48 postoperative hours (minimum average StO₂ percentage is $38\% \pm 8.8\%$ and the maximum average StO₂ percentage is $80.3\% \pm 12.7\%$), with final values above 70% (average $59\% \pm 14.2\%$ StO₂ percentage) and which are also above the initial StO₂ percentage (average $48\% \pm 7.6\%$ StO₂ percentage). Figure 5 shows the mentioned points with the ranges in time and StO₂ percentage in blue; the red curve is the 4-deg polynomial fit of the points.

Fig. 4 StO₂ percentage and naive Bayes classification results using overall patients' data. After time synchronization of all datasets, data are analyzed and processed. (a) StO₂ percentage results using the combined datasets of all patients. (b) Combined StO₂ results of all patients. (c) Naive Bayes classification using the combined hbO₂ and HHb datasets of all patients.

It provides a general pattern of the StO₂ percentage evolution over time.

Figure 4(b) also shows a 4-deg polynomial fit over the points from all datasets combined and synchronized. All combined

Table 2 Gaussian parameters for the naive Bayes classifier of the partial venous occlusion distinction.

Classes	Parameters (k)		
	Mean (μ_{C_k})	std (σ_{C_k})	$P(C_k)$
0% occlusion	91.166	4.489	0.4
25% occlusion	90.809	2.523	0.2
50% occlusion	92.103	2.299	0.13
75% occlusion	155.173	15.302	0.19
100% occlusion	158.336	20.899	0.06

Note: Std, standard deviation; $P(C_k)$, prior probability of the classification; k , {0% occlusion, 25% occlusion, 50% occlusion, 75% occlusion, 100% occlusion}.¹⁷

Fig. 5 Fitted pattern of the average StO₂ results of all patients with a 4-deg polynomial fit.

datasets and the resulting polynomial fit have a similar shape. Taken separately, each StO₂ percentage dataset has a similar polynomial fit. Table 3 shows the coefficients of the polynomial fit of the StO₂ percentage taken for each patients, the combined datasets, and the fitted pattern.

Using the Bayesian classifier trained with data from different partial venous occlusion levels emulated with synthetic venous blood and a vascular phantom [see Eq. (6) and Table 2], the acquired data of all patients, taken at different postoperative hours, were separately placed within the trained classifier. Figure 4(c) shows the occlusion-level classification of the data, with the posterior probability of the data to be attributed to the 0% occlusion level (or release) class, taken at postoperative hours 3, 7, 24, and 48. Results show that in the early postoperative hours the data are more clustered in the higher occlusion levels, whereas data acquired later are shifted to the lower occlusion levels with an increased posterior probability of an observation to be clustered in the 0% occlusion (release) class.

Using the vitals taken at regular intervals during the 48 h of monitoring, the correlation coefficients of the StO₂ percentage and, respectively, the blood pressure (based on the average of

Table 3 Coefficients of the polynomial fit of the StO₂ datasets.

StO ₂ dataset ID	$p \times 10^{-4}$	$q \times 10^{-3}$	$r \times 10^{-1}$	s	t
1	3	-0.9	-3.480	6.1064	50.5524
2	12	-4.7	6.881	-3.0004	5.7266
3	-2	2.8	0.951	-0.8766	50.3069
4	-1	5.8	-1.195	0.8802	48.6621
5	0	1.5	-0.667	0.7655	50.9731
6	-12	40.5	-5.455	2.7363	50.8872
7	1	-2.5	-0.040	0.4956	52.5724
8	7	-20.2	2.093	0.4914	49.2953
9	-6	22.0	-3.580	2.5699	46.4645
10	-1	-5.5	2.223	-2.0088	58.9165
11	-4	19.0	-3.850	3.1210	45.7532
12	-3	10.8	-1.479	1.4691	38.5091
13	0	4.2	-1.169	1.0991	60.6927
14	-9	35.6	-5.313	2.6641	46.7815
15	11	-21.0	0.525	1.2129	50.31287
16	-3	12.4	-2.117	0.5980	50.6841
Averaged coefficients synchronized	-4	6.2	-0.979	1.1452	47.3182
Data	-6	29.6	-6.746	5.6842	50.9053
Fitted pattern	-2	18.5	-6.901	8.1902	48.7902

The 4-deg polynomial fit is derived as $\text{StO}_2\% = p * \text{time}^4 + q * \text{time}^3 + r * \text{time}^2 + s * \text{time} + t$, with $\forall p, q, r, s, t \in \mathbb{R}$.

the systolic and diastolic blood pressure—average 0.53 ± 0.36), the heart rate (average 0.54 ± 0.36), the respiratory rate (average 0.49 ± 0.33), and the arterial oxygenation (average 0.54 ± 0.36) were analyzed.

In general, for all patients, the disconnection time between the device and the tablet was $<1\%$ (average $0.64\% \pm 0.39\%$) over the total 48 h monitoring time. The lost data were extrapolated and did not affect the final data analysis results.

The StO₂ results from the excised discarded tissue show a sharp decrease over the 3-h monitoring time (see Fig. 6). On the contrary, the StO₂ pattern in the case of successful FTT shows a sharp increase within the first 3-h period. These outcomes are coherent with the biological response of FTT^{24–27} and previous results¹⁷ and suggest that the device can properly monitor StO₂ variations in human tissue with different vascular health status.

On the excised discarded tissue, there is a decrease of about 10% StO₂ per hour (see Fig. 6). On healthy FTT, from about 10 to 30h after surgery, StO₂ decreases about 1% StO₂ per hour [see Figs. 4(b) and 5]. These results suggest that in a case of

Fig. 6 The ΔStO_2 results from excised discarded tissue. Variations in the decay following excision of tissue are expected as clinical parameters, such as temperature and peripheral vasoconstriction, will vary from patient to patient regardless of weight of tissue excised, as well as the condition of the tissue prior to excision (i.e., there may be some relative ischemia given that the tissue was not planned to be used for transfer). BMI, body mass index; ST, skin tone. (a) The ΔStO_2 percentage results on human excised discarded tissue. Tissue weight = 460 g, patient age = 60, BMI = healthy, ST = 3. (b) The ΔStO_2 percentage results on human excised discarded tissue. Tissue weight = 80 g, patient age = 47, BMI = overweight, ST = 3.

a VC occurring after 10 postoperative hours, the strength of the slope of StO₂ can indicate on the viability of the FTT, which is quantifiable using Eqs. (4) and (5).

5 Discussion

FTT is a complex but common plastic surgery that requires close postoperative monitoring to prevent failure. To do so, the clinical team regularly assesses the FTT with observations and palpations. However, to increase salvage rate and reduce staff burden, automatic continuous monitoring devices have been developed and commercialized; NIRS has been specifically shown to be a reliable, noninvasive technique to promptly detect FTT VC.

A compact device that uses NIRS has been developed for the continuous monitoring of StO₂ percentage. This noninvasive device is wireless and connects with a smart-device for real-time data analysis, visualization, and storage. Integrated with cloud computing, external users can remotely access the data in real time.^{19,20} The device has been designed to benefit both the patient and the clinical team by providing real-time and reliable data, independent of the patient's demographics. The steadfast embedded software and network provide complete self-management and recovery schemes with limited need for human input. The device has previously been tested on vascular phantom, animals, and healthy subjects. Results show that the device provides reliable and consistent outcomes for patients of different demographics (e.g., sex, age, BMI, or skin tone) and can provide an estimation of the blood occlusion level.¹⁷ Following ethical approval, the device has been tested in a clinical study on patients who underwent FTT for breast reconstructive surgery following mastectomy, for which the results are introduced in this paper. A total of 16 FTTs, which showed no complications, were monitored for 48 h after the surgery. The system has been shown to properly integrate into the clinical setting with ease and no disruption to the clinical staff. The device can robustly, reliably, and continuously monitor StO₂ percentage in FTT in a clinical setting, independent of the patient's demographics. Artifacts related to motion and ambient light are respectively eliminated with the adherent skin tape, allowing fixed placement, and the opaque casing preventing the ambient light to affect the measurements.

Specifically, the StO₂ percentage patterns observed from tissue with different vascular health status are coherent and can be attributed to the biological response of the perforators and the FTT, which have previously been reported.^{24–27} Indeed, autonomic denervation, inflammatory reaction, and ischemia of the FTT, normally induced by the operation, increase the StO₂ percentage within the FTT. An increase in the StO₂ percentage increases the blood flow at the pedicles, which decreases the vascular resistance to dilate the microcirculation within the FTT. These also dissolve any possible microthrombosis and repair micronecrosis.^{25,28,29} Although the significance of these reactions can vary according to the patient's vascular pattern, smoking or alcohol abuse, demographics, comorbidities, or age,^{28,30,31} which can affect the measurements, the StO₂ percentage trend pattern should remain the same.²⁹ Over the first 3 days after surgery, the pattern of the StO₂ percentage in the case of a successful FTT usually shows a sharp increase at first, followed by a steady decrease to finally plateau at a slightly lower percentage compared to its initial value.^{18,27,29}

In addition to real-time StO₂ percentage data analysis and visualization, averaged StO₂ percentage over time window and StO₂ percentage gradient variation display can help in understanding the health of the FTT and assess if the tissue should be closely monitored or has entered an StO₂ percentage equilibrium with unalarming small StO₂ percentage variations. Real-time classification of the StO₂ percentage according to the estimated blood vessel occlusion can be an additional parameter to assess the health of the FTT. These outcomes are sufficient to provide a case-by-case analysis.

Future work includes (1) recruiting a sizeable patient population to obtain more datasets with a range of different outcomes and patients' demographics to assert the given results, (2) StO₂ pattern modeling in different scenarios and data prediction,³² and (3) more data about the device and its network could also

be obtained for further optimization, scaling, and updates of current schemes to ensure data privacy and security.

6 Conclusion

This paper introduces the results of the clinical study of the post-operative monitoring of FTT for the reconstruction of breast following mastectomy using the developed optoelectronic device. The device is designed to meet the needs of the patients and the clinical team as it is wireless, ubiquitous, inexpensive, pervasive, compact, and small. Results concur with previous animal studies and show that the device can accurately measure StO₂ percentage variations in human tissue. The real-time data visualization and 30-min slots of data analysis provide sufficient information to deduce the health of the FTT. Future work consists in a larger multicentered study to acquire more datasets from a larger range of patients and reconstructive surgeries to assert the findings.

Disclosures

No conflicts of interest.

Acknowledgments

This study was supported by EPSRC Smart Sensing for Surgery (EP/LO14149/1) and the EPSRC CDT HiPEDS (EP/LO16796/1).

References

1. K.-T. Chen et al., "Timing of presentation of the first signs of vascular compromise dictates the salvage outcome of free flap transfers," *Plastic Reconstr. Surg.* **120**(1), 187–195 (2007).
2. M. Berthelot et al., "Wireless wearable self-calibrated sensor for perfusion assessment of myocutaneous tissue," in *IEEE 13th Int. Conf. Wearable and Implantable Body Sensor Networks (BSN)*, IEEE, pp. 171–176 (2016).
3. A. H. Chao et al., "A review of devices used in the monitoring of microvascular free tissue transfers," *Expert Rev. Med. Devices* **10**(5), 649–660 (2013).
4. C. Mourouzis et al., "Microdialysis: use in the assessment of a buried bone-only fibular free flap," *Plastic Reconstr. Surg.* **120**(5), 1363–1366 (2007).
5. N. Sinis et al., "Free flap monitoring with continuous tissue oxygen tension measurement," *Eur. J. Plastic Surg.* **28**(8), 507–512 (2006).
6. E. I. Chang et al., "Deciphering the sensitivity and specificity of the implantable Doppler probe in free flap monitoring," *Plastic Reconstr. Surg.* **137**(3), 971–976 (2016).
7. W. M. Swartz et al., "Direct monitoring of microvascular anastomoses with the 20-mhz ultrasonic Doppler probe: an experimental and clinical study," *Plastic Reconstr. Surg.* **81**(2), 149–158 (1988).
8. W. M. Swartz, R. Izquierdo, and M. J. Miller, "Implantable venous Doppler microvascular monitoring: laboratory investigation and clinical results," *Plastic Reconstr. Surg.* **93**(1), 152–163 (1994).
9. Y. Kagaya and S. Miyamoto, "A systematic review of near-infrared spectroscopy in flap monitoring: current basic and clinical evidence and prospects," *J. Plastic Reconstr. Aesthetic Surg.* **71**(2), 246–257 (2018).
10. B. Amirak et al., "Skin anatomy. Medscape," 2017, <https://emedicine.medscape.com/article/1294744-overview> (28 May 2019).
11. E. Wassenaar and J. Van den Brand, "Reliability of near-infrared spectroscopy in people with dark skin pigmentation," *J. Clin. Monit. Comput.* **19**(3), 195–199 (2005).
12. L. Fuller and E. Higgins, "Racial influences on skin disease," in *Rook's Textbook of Dermatology*, 8th ed., pp. 1–19, Blackwell Publishing Ltd., West Sussex (2010).
13. K. Hayashi et al., "Stiffness and elastic behavior of human intracranial and extracranial arteries," *J. Biomech.* **13**(2), 175–184 (1980).
14. C. Archer, "Functions of the skin," in *Rook's Textbook of Dermatology*, 8th ed., pp. 1–11, Blackwell Publishing Ltd., West Sussex (2010).

15. M. W. Wukitsch et al., "Pulse oximetry: analysis of theory, technology, and practice," *J. Clin. Monit.* **4**(4), 290–301 (1988).
16. D. McGibbon, "Subcutaneous fat," in *Rook's Textbook of Dermatology*, 8th ed., pp. 1–49, Blackwell Publishing Ltd., West Sussex (2010).
17. M. Berthelot, G.-Z. Yang, and B. Lo, "A self-calibrated tissue viability sensor for free flap monitoring," *IEEE J. Biomed. Health Inf.* **22**(1), 5–14 (2018).
18. M. Berthelot et al., "Pilot study: free flap monitoring using a new tissue oxygen saturation (sto₂) device," *Eur. J. Surg. Oncol.* **44**(6), 900 (2018).
19. S. Li, L. Xu, and S. Zhao, "The internet of things: a survey," *Inf. Syst. Front.* **17**(2), 243–259 (2015).
20. C. Bhatt, N. Dey, and A. S. Ashour, *Internet of Things and Big Data Technologies for Next Generation Healthcare*, Springer International Publishing, Cham (2017).
21. E. A. Lee and S. A. Seshia, *Introduction to Embedded Systems: A Cyber-Physical Systems Approach*, MIT Press, Cambridge, Massachusetts (2016).
22. A. Ponticorvo et al., "Quantitative assessment of partial vascular occlusions in a swine pedicle flap model using spatial frequency domain imaging," *Biomed. Opt. Express* **4**(2), 298–306 (2013).
23. M. L. Gimbel et al., "Monitoring partial and full venous outflow compromise in a rabbit skin flap model," *Plastic Reconstr. Surg.* **124**(3), 796–803 (2009).
24. A. Figus, A. Mosahebi, and V. Ramakrishnan, "Microcirculation in DIEP flaps: a study of the haemodynamics using laser Doppler flowmetry and lightguide reflectance spectrophotometry," *J. Plastic Reconstr. Aesthetic Surg.* **59**(6), 604–612 (2006).
25. F. Hölzle et al., "Free flap monitoring using simultaneous non-invasive laser Doppler flowmetry and tissue spectrophotometry," *J. Cranio-maxillo-facial Surg.* **34**(1), 25–33 (2006).
26. A. F. Mericli et al., "A prospective clinical trial comparing visible light spectroscopy to handheld Doppler for postoperative free tissue transfer monitoring," *Plastic Reconstr. Surg.* **140**(3), 604–613 (2017).
27. A. Najefi et al., "Monitoring of free flaps using near-infrared spectroscopy: a systematic review of the initial trials," *Plastic Reconstr. Surg.* **125**(4), 182e–184e (2010).
28. S. Schultze-Mosgau et al., "Micro-lightguide spectrophotometry as an intraoral monitoring method in free vascular soft tissue flaps," *J. Oral Maxillofacial Surg.* **61**(3), 292–297 (2003).
29. L. Raittinen et al., "How we do it: postoperative tissue oxygen monitoring in microvascular free flaps," *Clin. Otolaryngol.* **30**(3), 276–278 (2005).
30. C. N. Ozturk et al., "Variables affecting postoperative tissue perfusion monitoring in free flap breast reconstruction," *Microsurgery* **35**(2), 123–128 (2015).
31. R. Jonas et al., "Monitoring in microvascular tissue transfer by measurement of oxygen partial pressure: four years experience with 125 microsurgical transplants," *J. Cranio-Maxillo-Facial Surg.* **41**(4), 303–309 (2013).
32. D. Rav et al., "Deep learning for health informatics," *IEEE J. Biomed. Health Inf.* **21**(1), 4–21 (2017).

Biographies of the authors are not available.